Simulating HIV Breakthrough and Resistance Development During Variable Adherence to Antiretroviral Treatment.
Journal
Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005
Informations de publication
Date de publication:
01 03 2021
01 03 2021
Historique:
received:
24
07
2020
accepted:
26
10
2020
pubmed:
17
11
2020
medline:
27
8
2021
entrez:
16
11
2020
Statut:
ppublish
Résumé
Barriers to lifelong HIV-1 suppression by antiretrovirals include poor adherence and drug resistance; regimens with higher tolerance to missed doses (forgiveness) would be beneficial to patients. To model short-term nonadherence, in vitro experiments monitoring viral breakthrough (VB) and resistance development were conducted. HIV breakthrough experiments simulated drug exposures at full adherence or suboptimal adherence to bictegravir+emtricitabine+tenofovir alafenamide (BIC+FTC+TAF) or dolutegravir + lamivudine (DTG+3TC). MT-2 cells were infected with wild-type or low frequency M184V HIV-1, exposed to drug combinations, monitored for VB, and rebound virus was deep sequenced. Drug concentrations were determined using human plasma-free adjusted clinical trough concentrations (Cmin), at simulated Cmin after missing 1 to 3 consecutive doses (Cmin - 1 or Cmin - 2, and Cmin - 3) based on drug or active metabolite half-lives. Cultures infected with wild-type or low frequency M184V HIV-1 showed no VB with BIC+FTC+TAF at drug concentrations corresponding to Cmin, Cmin - 1, or Cmin - 2 but breakthrough did occur in 26 of 36 cultures at Cmin - 3, where the M184V variant emerged in one culture. Experiments using DTG + 3TC prevented most breakthrough at Cmin concentrations (9/60 had breakthrough) but showed more breakthroughs as drug concentrations decreased (up to 36/36) and variants associated with resistance to both drugs emerged in some cases. These in vitro VB results suggest that the high potency, long half-lives, and antiviral synergy provided by the BIC/FTC/TAF triple therapy regimen may protect from viral rebound and resistance development after short-term lapses in drug adherence.
Sections du résumé
BACKGROUND
Barriers to lifelong HIV-1 suppression by antiretrovirals include poor adherence and drug resistance; regimens with higher tolerance to missed doses (forgiveness) would be beneficial to patients. To model short-term nonadherence, in vitro experiments monitoring viral breakthrough (VB) and resistance development were conducted.
METHODS
HIV breakthrough experiments simulated drug exposures at full adherence or suboptimal adherence to bictegravir+emtricitabine+tenofovir alafenamide (BIC+FTC+TAF) or dolutegravir + lamivudine (DTG+3TC). MT-2 cells were infected with wild-type or low frequency M184V HIV-1, exposed to drug combinations, monitored for VB, and rebound virus was deep sequenced. Drug concentrations were determined using human plasma-free adjusted clinical trough concentrations (Cmin), at simulated Cmin after missing 1 to 3 consecutive doses (Cmin - 1 or Cmin - 2, and Cmin - 3) based on drug or active metabolite half-lives.
RESULTS
Cultures infected with wild-type or low frequency M184V HIV-1 showed no VB with BIC+FTC+TAF at drug concentrations corresponding to Cmin, Cmin - 1, or Cmin - 2 but breakthrough did occur in 26 of 36 cultures at Cmin - 3, where the M184V variant emerged in one culture. Experiments using DTG + 3TC prevented most breakthrough at Cmin concentrations (9/60 had breakthrough) but showed more breakthroughs as drug concentrations decreased (up to 36/36) and variants associated with resistance to both drugs emerged in some cases.
CONCLUSIONS
These in vitro VB results suggest that the high potency, long half-lives, and antiviral synergy provided by the BIC/FTC/TAF triple therapy regimen may protect from viral rebound and resistance development after short-term lapses in drug adherence.
Identifiants
pubmed: 33196554
pii: 00126334-202103010-00017
doi: 10.1097/QAI.0000000000002562
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
369-377Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Références
Clutter DS, Jordan MR, Bertagnolio S, et al. HIV-1 drug resistance and resistance testing. Infect Genet Evol. 2016;46:292–307.
Tsiang M, Jones GS, Goldsmith J, et al. Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile. Antimicrob Agents Chemother. 2016;60:7086–7097.
Schinazi RF, Lloyd RM, Nguyen MH, et al. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother. 1993;37:875–881.
Tisdale M, Kemp SD, Parry NR, et al. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A. 1993;90:5653–5656.
Wainberg MA, Moisi D, Oliveira M, et al. Transmission dynamics of the M184V drug resistance mutation in primary HIV infection. J Antimicrob Chemother. 2011;66:2346–2349.
Yoshinaga T, Kobayashi M, Seki T, et al. Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection. Antimicrob Agents Chemother. 2015;59:397–406.
Wijting I, Rokx C, Boucher C, et al. Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial. Lancet HIV. 2017;4:e547–54.
Yoshinaga T, Miki S, Kawauchi-Miki S, et al. Barrier to resistance of dolutegravir in two-drug combinations. Antimicrob Agents Chemother. 2019;63:e02104–18.
Margot NA, Waters JM, Miller MD. In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine. Antimicrob Agents Chemother. 2006;50:4087–4095.
Mulato A, Hansen D, Thielen A, et al. Rapid in vitro evaluation of antiretroviral barrier to resistance at therapeutic drug levels. AIDS Res Hum Retroviruses. 2016;32:1237–1247.
Haertle T, Carrera CJ, Wasson DB, et al. Metabolism and anti-human immunodeficiency virus-1 activity of 2-halo-2',3'-dideoxyadenosine derivatives. J Biol Chem. 1988;263:5870–5875.
Harada S, Koyanagi Y, Yamamoto N. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science. 1985;229:563–566.
Shi C, Mellors JW. A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors. Antimicrob Agents Chemother. 1997;41:2781–2785.
BIKTARVY and Gilead Sciences Inc., BIKTARVY® (Bictegravir, Emtricitabine, and Tenofovir Alafenamide) Tablets, for Oral Use. Foster City, CA: U. S. Prescribing Information; 2019.
DOVATO and GlaxoSmithKline, DOVATO (Dolutegravir and Lamivudine) Tablets, for Oral Use. Research Triangle Park, NC: U. S. Prescribing Information; 2019.
Mo H, Yang C, Wang K, et al. Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors. J Viral Hepat. 2011;18:338–348.
Callebaut C, Liu Y, Babusis D, et al. Viability of primary osteoblasts after treatment with tenofovir alafenamide: lack of cytotoxicity at clinically relevant drug concentrations. PLoS One. 2017;12:e0169948.
Dickinson L, Yapa HM, Jackson A, et al. Plasma tenofovir, emtricitabine, and rilpivirine and intracellular tenofovir diphosphate and emtricitabine triphosphate pharmacokinetics following drug intake cessation. Antimicrob Agents Chemother. 2015;59:6080–6086.
Yuen GJ, Lou Y, Bumgarner NF, et al. Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily. Antimicrob Agents Chemother. 2004;48:176–182.
Svarovskaia ES, Dvory-Sobol H, Parkin N, et al. Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis. 2014;59:1666–1674.
Donaldson EF, Harrington PR, O'Rear JJ, et al. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology. 2015;61:56–65.
Lee WA, He GX, Eisenberg E, et al. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob Agents Chemother. 2005;49:1898–1906.
Custodio J, West SK, Lutz J, et al. Twice daily administration of tenofovir alafenamide in combination with Rifampin: potential for tenofovir alafenamide use in HIV-TB coinfection [presentation]. European AIDS Clinical Society (EACS). 2017. Milan, Italy.
Else LJ, Jackson A, Puls R, et al. Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study. Antimicrob Agents Chemother. 2012;56:1427–1433.
Mesplède T, Quashie PK, Osman N, et al. Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology. 2013;10:22.
Quashie PK, Mesplède T, Han YS, et al. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol. 2012;86:2696–2705.
Andreatta K, Chang S, Martin R, et al. Integrase inhibitor resistance selections initiated with drug resistant HIV-1 [poster 546]. Conference on Retroviruses and Opportunistic Infections (CROI). 2018. Boston, MA.
Kobayashi M, Yoshinaga T, Seki T, et al. In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother. 2011;55:813–821.
Smith SJ, Zhao XZ, Burke TR, et al. Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants. Retrovirology. 2018;15:37.
Rhee SY, Gonzales MJ, Kantor R, et al. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 2003;31:298–303.
Shafer RW. Rationale and uses of a public HIV drug-resistance database. J Infect Dis. 2006;194(suppl 1):S51–S58.
Winters MA, Lloyd RM, Shafer RW, et al. Development of elvitegravir resistance and linkage of integrase inhibitor mutations with protease and reverse transcriptase resistance mutations. PLoS One. 2012;7:e40514.
Pennings PS, Kryazhimskiy S, Wakeley J. Loss and Recovery of genetic diversity in adapting populations of HIV. PLoS Genet. 2014;10:e1004000.
Buckton AJ, Prabhu D, Motamed C, et al. Increased detection of the HIV-1 reverse transcriptase M184V mutation using mutation-specific minority assays in a UK surveillance study suggests evidence of unrecognized transmitted drug resistance. HIV Med. 2011;12:250–254.
Rusconi S, De Pasquale MP, Milazzo L, et al. Loss of lamivudine resistance in a zidovudine and lamivudine dual-resistant HIV-1 isolate after discontinuation of in vitro lamivudine drug pressure. Antivir Ther. 1998;3:203–207.
Andreatta K, Willkom M, Martin R, et al. Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I. J Antimicrob Chemother. 2019:74:3555–3564.
Margot N, Ram R, McNicholl IR, et al. Differential detection of M184V/I between plasma historical HIV genotypes and proviral DNA from PBMCs [poster MOPEB249]. 10th IAS Conference on HIV Science (IAS 2019). 2019. Mexico City, Mexico.
Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 Recommendations of the international antiviral society-USA panel. JAMA. 2018;320:379–396.
World Health Organization (WHO), Updated Recommendations on First-Line and Second-Line Antiretroviral Regimens and Post-Exposure Prophylaxis and Recommendations on Early Infant Diagnosis of HIV. Supplement to the 2016 Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. WHO; 2018. Available at: https://www.who.int/publications/guidelines/hiv_aids/en/ .
European AIDS Clinical Society (EACS), the EACS Guidelines Version 10. English. EACS; 2019. Available at: https://eacs.sanfordguide.com/ .
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV. Department of Health and Human Services. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf . Last Updated: 18 December, 2019.
Cheng Y, Nickman NA, Jamjian C, et al. Predicting poor adherence to antiretroviral therapy among treatment-naïve veterans infected with human immunodeficiency virus. Medicine (Baltimore). 2018;97:e9495.
Tandon N, Mao J, Shprecher A, et al. Compliance with clinical guidelines and adherence to antiretroviral therapy among patients living with HIV. Curr Med Res Opin. 2018;35:63–71.
Kangethe A, Polson M, Lord TC, et al. Real-world health plan data analysis: key trends in medication adherence and overall costs in patients with HIV. J Manag Care Spec Pharm. 2019;25:88–93.
Cohen CJ, Colson AE, Sheble-Hall AG, et al. Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) study. HIV Clin Trials. 2007;8:19–23.
Landman R, De Truchis P, Assoumou L, et al. ANRS 170 QUATUOR 4/7 Days maintenance strategy in antiretroviral treated adults with HIV-1 infection: an open randomized parallel non-inferiority phase III trial [presentation]. 10th IAS Conference on HIV Science. 2019. Mexico City, Mexico.
Reynolds SJ, Kityo C, Hallahan CW, et al. A randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral therapy for the treatment of HIV infection in Uganda. PLoS One. 2010;5:e10307.
Breather (PENTA 16) Trial Group. Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial. Lancet HIV. 2016;3:e421–e430.
de Truchis P, Assoumou L, Landman R, et al. Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial. J Antimicrob Chemother. 2018;73:738–747.
Leibowitch J, Mathez D, de Truchis P, et al. Four days a week or less on appropriate anti-HIV drug combinations provided long-term optimal maintenance in 94 patients: the ICCARRE project. FASEB J. 2015;29:2223–2234.
Walmsley S, Baumgarten A, Berenguer J, et al. Brief report: dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial. J Acquir Immune Defic Syndr. 2015;70:515–519.
Orkin C, DeJesus E, Sax PE, et al. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials [Supplementary Appendix]. Lancet HIV. 2020;7:e389–e400.
Raffi F, Rachlis A, Stellbrink HJ, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381:735–743.
Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369:1807–1818.
Clotet B, Feinberg J, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet. 2014;383:2222–2231.
Aboud M, Orkin C, Podzamczer D, et al. Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies. Lancet HIV. 2019;6:e576–e587.
Cahn P, Madero JS, Arribas JR, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019;393:143–155.
Nyaku AN, Zheng L, Gulick RM, et al. Dolutegravir plus Lamivudine for initial Treatment of HIV-1-Infected Participants with HIV-1 RNA <500 000 copies/mL: week 48 Outcomes from ACTG 5353. J Antimicrob Chemother. 2019;74:1376–1380.
Cahn P, et al. Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment-naive adults with HIV-1 infection—3-year results from the gemini studies [poster 018]. HIV GLASGOW Drug Therapy Virtual. 2020. Glasgow, UK.
Borroto-Esoda K, Vela JE, Myrick F, et al. In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine. Antivir Ther. 2006;11:377–384.
Laskey SB, Siliciano RF. Quantitative evaluation of the antiretroviral efficacy of dolutegravir. JCI Insight. 2016;1:e90033.
Kulkarni R, Feng JY, Miller MD, et al. Dead-end complexes contribute to the synergistic inhibition of HIV-1 RT by the combination of rilpivirine, emtricitabine, and tenofovir. Antivir Res. 2014;101:131–135.
Deval J, White KL, Miller MD, et al. Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J Biol Chem. 2004;279:509–516.
Wainberg MA, Miller MD, Quan Y, et al. In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther. 1999;4:87–94.
Miller MD, Haddad M, Su C, et al. Trends in HIV-1 reverse transcriptase resistance-associated mutations and antiretroviral prescription data from 2003-2010. Antivir Ther. 2012;17:993–999.
Marconi VC, Sunpath H, Lu Z, et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis. 2008;46:1589–1597.
Karkashadze E, Dvali N, Bolokadze N, et al. Epidemiology of HIV drug resistance in HIV patients with virologic failure of first-line therapy in the country of Georgia. J Med Virol. 2018;91:235–240.
Cheng CY, Tsai MS, Yang CJ, et al. Patterns of emergent resistance-associated mutations after initiation of non-nucleoside reverse-transcriptase inhibitor-containing antiretroviral regimens in taiwan: a multicenter cohort study. Infect Drug Resist. 2018;11:849–859.
Acosta R, Willkom M, Andreatta K, et al. Keeping the pressure on archived NRTI resistance: switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) triple therapy in study 4030 [poster MOPEB241]. 10th IAS Conference on HIV Science (IAS 2019). 2019. Mexico City, Mexico.
Olearo F, Nguyen H, Bonnet F, et al. Impact of the M184V/I mutation on the efficacy of abacavir/lamivudine/dolutegravir therapy in HIV treatment-experienced patients. Open Forum Infect Dis. 2019;6:ofz330.
Pronier C, Maillard A, Comacle P, et al. Successful switch to once-daily single-tablet regimen (STR) containing elvitegravir (EVG) or dolutegravir (DTG) in virologically suppressed HIV-1-Infected patients despite archived resistant quasispecies [Abstract]. IAS. 2017. Paris, France.
De Miguel R, Rial-Crestelo D, Dominguez-Dominguez L, et al. Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO). EBioMed. 2020;55:102779.
van Wyk J, Ajana F, Bisshop F, et al. Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose two-drug regimen versus continuing a tenofovir alafenamide-based three- or four-drug regimen for maintenance of virologic suppression in adults with HIV-1: phase 3, randomized, non-inferiority TANGO study. Clin Infect Dis. 2020;71:1920–1929.
Katlama C, Soulié C, Caby F, et al. Dolutegravir as monotherapy in HIV-1-Infected individuals with suppressed HIV viraemia. J Antimicrob Chemother. 2016;71:2646–2650.
Blanco JL, Rojas J, Paredes R, et al. Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 Week analysis of the DOLAM randomized clinical trial. J Antimicrob Chemother. 2018;73:1965–1971.
Oldenbuettel C, Wolf E, Ritter A, et al. Dolutegravir monotherapy as treatment de-escalation in HIV-infected adults with virological control: DoluMono cohort results [Abstract]. Antivir Ther. 2017;22:169–172.
Gagliardini R, Ciccullo A, Borghetti A, et al. Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with suppressed HIV-1 RNA: a cohort study. Open Forum Infect Dis. 2018;5:ofy113.
De Miguel Buckley R, Rial-Crestelo D, Dominguez-Dominguez L, et al. Dolutegravir and lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a pilot clinical trial (ART-PRO) [abstract PS7/5]. 17th European AIDS Conference. 2019. Basel, Switzerland.
Baldin G, Ciccullo A, Rusconi S, et al. Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients. Int J Antimicrob Agents. 2019;54:728–734.